Shares of the WuXi family of biotech and research companies fell sharply after a U.S. bill targeting certain Chinese biotechnology providers got the green light to go to the Senate floor, reigniting worries about potential U.S. sanctions. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
